This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The guidelines determined the appropriate administration of low-molecular-weight heparin, for eight days, on the basis of the patient's risk of venous thromboembolism (low, intermediate, high, or very high) . The comparator was no clinical guidelines.
Location/setting
Italy/hospital.
Methods

Analytical approach:
The analysis was based on a decision-tree model, with a short horizon of the length of hospital stay. The authors stated that a hospital perspective was adopted.
Effectiveness data:
The clinical inputs were estimated using two approaches. The prophylaxis-related data, which were the proportion of patients receiving prophylaxis by risk group before and after the introduction of the guidelines, were from an audit of two random sets of 250 patients, who were discharged in the first half of 2000 and 2002 from an Italian teaching hospital. The remaining data were identified by a literature review. The efficacy of prophylaxis was the key clinical input and this was from the literature.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
The proportion of event-free patients was the benefit measure.
Cost data:
Two main cost categories were included: the costs of prophylaxis (administration of low-molecular-weight heparin, major bleeding due to prophylaxis, and elastic stockings) and the costs of venous thromboembolism-related events (deep venous thrombosis and pulmonary embolism). Most of the costs and resource use data were from Italian
